Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Oct;83(10):2325-2329.
doi: 10.1111/bcp.13366. Epub 2017 Aug 1.

Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting

Alper Daskapan  1 , Desie Dijkema  2 , Dorien A de Weerd  3 , Wouter F W Bierman  3 , Jos G W Kosterink  1   4 , Tjip S van der Werf  3 , Jan-Willem C Alffenaar  1 , Ymkje Stienstra  3
Affiliations

Food intake and darunavir plasma concentrations in people living with HIV in an outpatient setting

Alper Daskapan et al. Br J Clin Pharmacol. 2017 Oct.

Abstract

Aims: Patients receiving darunavir are advised to take it concomitantly with food. The objectives of the present cross-sectional study were to evaluate the actual concomitant food intake of patients visiting an HIV outpatient clinic.

Methods: Sixty participants treated with darunavir/ritonavir once daily were subjected to a food recall questionnaire concerning their last concomitant food intake with darunavir. Darunavir trough concentrations were calculated.

Results: The median food intake was 507 (0-2707) kcal; protein intake, 20 (0-221)g; carbohydrate intake, 62 (0-267)g; fat intake: 14 (0-143)g; and dietary fibre: 4 (0-30)g. Twenty-five patients (42%) ingested their drug with between-meal snacks. No relationship was found between food intake and trough concentrations.

Conclusions: Clear advice on the optimal caloric intake is needed, to avoid high caloric intake in patients who already have an increased risk of cardiovascular disease due to their HIV infection.

Keywords: HIV/AIDS; antiretrovirals; clinical pharmacology; infectious diseases; patient safety; pharmacokinetics.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Scatter plot of energy intake (kcal) vs. the calculated darunavir (DRV) trough concentrations (Ctrough). The dotted line represents the reference population median Ctrough for the once‐daily dosage of DRV (1.07 mg l–1)
See this image and copyright information in PMC

References

    1. Ortiz R, Dejesus E, Khanlou H, Voronin E, van Lunzen J, Andrade‐Villanueva J, et al. Efficacy and safety of once‐daily darunavir/ritonavir versus lopinavir/ritonavir in treatment‐naive HIV‐1‐infected patients at week 48. AIDS 2008; 22: 1389–1397. - PubMed
    1. Arab‐Alameddine M, Lubomirov R, Fayet‐Mello A, Aouri M, Rotger M, Buclin T, et al. Swiss HIV Cohort Study . Population pharmacokinetic modelling and evaluation of different dosage regimens for darunavir and ritonavir in HIV‐infected individuals. J Antimicrob Chemother 2014; 69: 2489–2498. - PubMed
    1. Sekar V, Kestens D, Spinosa‐Guzman S, De Pauw M, De Paepe E, Vangeneugden T, et al. The effect of different meal types on the pharmacokinetics of darunavir (TMC114)/ritonavir in HIV‐negative healthy volunteers. J Clin Pharmacol 2007; 47: 479–484. - PubMed
    1. Janssen‐Cilag BV. Information for people who use Prezista®, PHNL/PRE/0113/0250 Edition. Netherlands: Janssen‐Cilag B.V., 2013.
    1. Janssen Therapeutics , Division of Janssen Products, LP . How should I take PREZISTA®?. Beerse, Belgium, 2014.